Literature DB >> 565877

Hypertriglyceridemia associated with deficiency of apolipoprotein C-II.

W C Breckenridge, J A Little, G Steiner, A Chow, M Poapst.   

Abstract

A 59-year-old man with severe hypertriglyceridemia and no post-heparin lipolytic activity was studied because of a marked fall in plasma triglyceride concentrations after a blood transfusion. An apolipoprotein activator (apolipoprotein C-II) for lipoprotein lipase could not be detected by polyacrylamide-gel electrophoresis of apoproteins, immunodiffusion of the plasma against anti-apolipoprotein CII or activation assays for lipoprotein lipase. Furthermore, the patient's triglyceride-rich lipoproteins would not serve as substrate for lipoprotein lipase. The patient had latent post-heparin lipolytic activity, which appeared after the addition of apolipoprotein CII to the post-heparin plasma. After a transfusion of 1 unit of plasma from a normal subject the patient's plasma triglycerides fell, within one day, from 1000 to 250 mg per deciliter and remained below preinfusion concentrations for six days. We conclude that this patient's hyperlipoproteinemia resulted from a deficiency of apolipoprotein C-II.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 565877     DOI: 10.1056/NEJM197806082982301

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  106 in total

Review 1.  Monogenic dyslipidemias: window on determinants of plasma lipoprotein metabolism.

Authors:  R A Hegele
Journal:  Am J Hum Genet       Date:  2001-10-26       Impact factor: 11.025

Review 2.  Regulation of the synthesis, processing and translocation of lipoprotein lipase.

Authors:  J E Braun; D L Severson
Journal:  Biochem J       Date:  1992-10-15       Impact factor: 3.857

Review 3.  Plasma lipoproteins, lipid transport, and atherosclerosis: recent developments.

Authors:  N E Miller
Journal:  J Clin Pathol       Date:  1979-07       Impact factor: 3.411

4.  The role of high density lipoprotein apolipoprotein CII in triglyceride metabolism.

Authors:  M L Kashyap; L S Srivastava; B A Hynd; G Perisutti; D W Brady; P Gartside; C J Glueck
Journal:  Lipids       Date:  1978-12       Impact factor: 1.880

Review 5.  Indications for lipid-lowering drugs.

Authors:  J Davignon
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

6.  Donor splice site mutation in the apolipoprotein (Apo) C-II gene (Apo C-IIHamburg) of a patient with Apo C-II deficiency.

Authors:  S S Fojo; U Beisiegel; U Beil; K Higuchi; M Bojanovski; R E Gregg; H Greten; H B Brewer
Journal:  J Clin Invest       Date:  1988-11       Impact factor: 14.808

7.  The natural history and surgical significance of hyperlipemic abdominal crisis.

Authors:  A Miller; R S Lees; M A McCluskey; A L Warshaw
Journal:  Ann Surg       Date:  1979-09       Impact factor: 12.969

8.  Activation of the phospholipase A1 activity of lipoprotein lipase by apoprotein C-II.

Authors:  J Stocks; D J Galton
Journal:  Lipids       Date:  1980-03       Impact factor: 1.880

9.  Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia. Reversal toward normal with bezafibrate treatment.

Authors:  S Eisenberg; D Gavish; Y Oschry; M Fainaru; R J Deckelbaum
Journal:  J Clin Invest       Date:  1984-08       Impact factor: 14.808

10.  Demonstration of an abnormality of C apoprotein of very low density lipoprotein in patients with gout.

Authors:  D G Macfarlane; C A Midwinter; P A Dieppe; C H Bolton; M Hartog
Journal:  Ann Rheum Dis       Date:  1985-06       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.